Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(−2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Valle, J W, Dangoor, A, Beech, J, Sherlock, D J, Lee, S M, Scarffe, J H, Swindell, R, Ranson, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361887/
https://www.ncbi.nlm.nih.gov/pubmed/15700038
http://dx.doi.org/10.1038/sj.bjc.6602394
Descripción
Sumario:Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(−2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.

Ejemplares similares